선택지 정리됨
Adrenocortical carcinoma: 국가별 선택지
이 페이지는 한국어 임상 치료 설명을 새로 쓰지 않습니다. 권위 출처, 진료 전 정리 질문, 임상시험 검색어, 구축 상태를 보여주는 안전한 시작점입니다.
선택지 정리됨고형암최종 확인 2026.06
현재 제공
국가별 선택지를 정리합니다
국가별로 출처가 연결된 선택지와 함께, 진단명·단계·검사 결과·진료과·임상시험 검색어를 정리합니다.
아직 하지 않음
치료 선택을 지시하지 않습니다
이 페이지는 치료 순위, 권장, 적합성 판단을 하지 않습니다.
출처
공신력 있는 출처 기반
모든 선택지는 규제·평가·지침 등 공신력 있는 출처에 연결되며, 새 출처가 검증되면 계속 확장됩니다.
진료 전 정리할 정보
- 이 항목은 원문 출처와 함께 의료진에게 확인하세요.
- 이 항목은 원문 출처와 함께 의료진에게 확인하세요.
- 이 항목은 원문 출처와 함께 의료진에게 확인하세요.
- 이 항목은 원문 출처와 함께 의료진에게 확인하세요.
임상시험 검색어
국가별 선택지
국가별 치료 선택지
공식 규제·평가 기관 출처를 바탕으로 한 국가별 승인·접근 상태입니다. 무엇이 어디에 존재하는지를 보여줄 뿐, 추천이 아닙니다.
United States
- Mitotane (Lysodren)[1]FDA-approvedFunctional versus nonfunctional hormonal status is clinically relevant; no genomic biomarker required by fetched U.S. label; Inoperable functional or nonfunctional ACC. · Label indication does not establish payer coverage, treatment suitability, or dosing for a specific patient. Label includes major safety updates and monitoring/handling precautions. Confidence/conflicts: High for U.S. labeled indication.
- Mitotane (Lysodren)[1]FDA-approvedFunctional versus nonfunctional hormonal status is clinically relevant; no genomic biomarker required by fetched U.S. label; Inoperable functional or nonfunctional ACC. · Label indication does not establish payer coverage, treatment suitability, or dosing for a specific patient. Label includes major safety updates and monitoring/handling precautions. Confidence/conflicts: High for U.S. labeled indication.
European Union
- Mitotane (Lysodren)[2]EMA authorisedFunctional hormone-producing status affects symptom benefit; no genomic biomarker required by fetched EMA source; Advanced unresectable, metastatic, or relapsed ACC; symptom treatment context per EMA wording. · EMA central authorisation does not establish member-state reimbursement, local specialist access, or individual eligibility. EMA notes limited evidence for some uses and the need for blood-level monitoring. Confidence/conflicts: High for EU authorised indication; national reimbursement remains unverified.
- Mitotane (Lysodren)[2]EMA authorisedFunctional hormone-producing status affects symptom benefit; no genomic biomarker required by fetched EMA source; Advanced unresectable, metastatic, or relapsed ACC; symptom treatment context per EMA wording. · EMA central authorisation does not establish member-state reimbursement, local specialist access, or individual eligibility. EMA notes limited evidence for some uses and the need for blood-level monitoring. Confidence/conflicts: High for EU authorised indication; national reimbursement remains unverified.
- Mitotane (Lysodren)[2]EMA authorisedFunctional hormone-producing status affects symptom benefit; no genomic biomarker required by fetched EMA source; Advanced unresectable, metastatic, or relapsed ACC; symptom treatment context per EMA wording. · EMA central authorisation does not establish member-state reimbursement, local specialist access, or individual eligibility. EMA notes limited evidence for some uses and the need for blood-level monitoring. Confidence/conflicts: High for EU authorised indication; national reimbursement remains unverified.
United Kingdom
- Mitotane (Lysodren), alone or with other chemotherapy drugs[3]ApprovedNo biomarker required by fetched UK source; Unresectable, relapsed, or metastatic ACC. · Cancer Research UK is a patient/professional cancer information charity, not MHRA/NICE. Exact UK licensing, commissioning, and local formulary status require separate regulator/NHS source verification. Confidence/conflicts: Medium-high for UK treatment-information context; exact MHRA/NICE status remains an active gap.
- Mitotane (Lysodren), alone or with other chemotherapy drugs[3]ApprovedNo biomarker required by fetched UK source; Unresectable, relapsed, or metastatic ACC. · Cancer Research UK is a patient/professional cancer information charity, not MHRA/NICE. Exact UK licensing, commissioning, and local formulary status require separate regulator/NHS source verification. Confidence/conflicts: Medium-high for UK treatment-information context; exact MHRA/NICE status remains an active gap.
출처
- DailyMed / U.S. FDA label — official drug label · official drug label
- European Medicines Agency (EMA) — regulator EPAR · regulator EPAR
- Cancer Research UK — UK cancer information / drug information · UK cancer information / drug information
위 내용은 공식 규제·접근 상태일 뿐, 의학적 조언이나 추천이 아니고, 적격성을 판단하지도 않습니다. 어떤 선택지가 적합한지는 환자의 상황과 종양내과 팀에 달려 있습니다. 규제 상태는 바뀔 수 있으니 표시된 출처에서 확인하세요. 임상 세부 내용은 영문이 정본입니다. 최종 확인 2026-06-12.